Zydus Lifesciences gets USFDA nod for Deflazacort oral suspension
[ad_1] Zydus Lifesciences Ltd on Monday said it has received final approval from the US health regulator for its generic version of Deflazacort oral suspension used in treating a severe form of inherited muscular dystrophy. The approval by the US Food and Drug Administration (USFDA) is for Deflazacort oral suspension of strength 22.75 mg/ml, Zydus…